Becton, Dickinson and Company (NYSE: BDX) Stock Competitors & Peer Comparison
See BDX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
| AVTR | $11.44 | +0.79% | 7.8B | 13.46 | $0.85 | N/A |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDXA)
BDX vs BDXA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BDX's ROE is +0.05%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
BDX vs MDLN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas MDLN's P/E ratio is 45.06. In terms of profitability, BDX's ROE is +0.05%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, BDX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BDX vs WST Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, WST has a market cap of 23.2B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while WST trades at $328.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas WST's P/E ratio is 41.19. In terms of profitability, BDX's ROE is +0.05%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDX is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BDX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BDX vs HOLX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDX's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BDX vs COO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas COO's P/E ratio is 15.42. In terms of profitability, BDX's ROE is +0.05%, compared to COO's ROE of +0.03%. Regarding short-term risk, BDX is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BDX.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BDX vs BDXB Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDX's ROE is +0.05%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BDX vs BAX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas BAX's P/E ratio is 10.77. In terms of profitability, BDX's ROE is +0.05%, compared to BAX's ROE of -0.16%. Regarding short-term risk, BDX is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
BDX vs ATR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ATR's P/E ratio is 23.13. In terms of profitability, BDX's ROE is +0.05%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDX is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
BDX vs AVTR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas AVTR's P/E ratio is 13.46. In terms of profitability, BDX's ROE is +0.05%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDX is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BDX vs RGEN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas RGEN's P/E ratio is 73.31. In terms of profitability, BDX's ROE is +0.05%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
BDX vs TFX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas TFX's P/E ratio is 12.32. In terms of profitability, BDX's ROE is +0.05%, compared to TFX's ROE of -0.28%. Regarding short-term risk, BDX is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BDX vs BLCO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas BLCO's P/E ratio is 24.88. In terms of profitability, BDX's ROE is +0.05%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDX is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BDX.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BDX vs STVN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas STVN's P/E ratio is 31.81. In terms of profitability, BDX's ROE is +0.05%, compared to STVN's ROE of +0.10%. Regarding short-term risk, BDX is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BDX vs MMSI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas MMSI's P/E ratio is 19.01. In terms of profitability, BDX's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BDX vs ICUI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ICUI's P/E ratio is 19.66. In terms of profitability, BDX's ROE is +0.05%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
BDX vs HAE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas HAE's P/E ratio is 15.86. In terms of profitability, BDX's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, BDX is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for BDX.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BDX vs XRAY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas XRAY's P/E ratio is 9.04. In terms of profitability, BDX's ROE is +0.05%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, BDX is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BDX vs LMAT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas LMAT's P/E ratio is 37.05. In terms of profitability, BDX's ROE is +0.05%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BDX vs PLSE Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas PLSE's P/E ratio is -27.48. In terms of profitability, BDX's ROE is +0.05%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, BDX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BDX vs ATRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, BDX's ROE is +0.05%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BDX vs BLFS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas BLFS's P/E ratio is -141.85. In terms of profitability, BDX's ROE is +0.05%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, BDX is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
BDX vs AZTA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas AZTA's P/E ratio is 60.82. In terms of profitability, BDX's ROE is +0.05%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, BDX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BDX vs KMTS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas KMTS's P/E ratio is -8.92. In terms of profitability, BDX's ROE is +0.05%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, BDX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BDX vs STAA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas STAA's P/E ratio is 41.02. In terms of profitability, BDX's ROE is +0.05%, compared to STAA's ROE of -0.06%. Regarding short-term risk, BDX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
BDX vs QDEL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas QDEL's P/E ratio is 11.98. In terms of profitability, BDX's ROE is +0.05%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, BDX is less volatile compared to QDEL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
BDX vs ATRI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDX's ROE is +0.05%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BDX vs ANGO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ANGO's P/E ratio is -34.85. In terms of profitability, BDX's ROE is +0.05%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDX is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BDX vs NNNN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas NNNN's P/E ratio is 145.38. In terms of profitability, BDX's ROE is +0.05%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BDX vs OSUR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas OSUR's P/E ratio is -4.78. In terms of profitability, BDX's ROE is +0.05%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, BDX is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BDX vs SMTI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas SMTI's P/E ratio is -426.00. In terms of profitability, BDX's ROE is +0.05%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, BDX is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BDX vs UTMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas UTMD's P/E ratio is 19.86. In terms of profitability, BDX's ROE is +0.05%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
BDX vs INFU Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas INFU's P/E ratio is 23.97. In terms of profitability, BDX's ROE is +0.05%, compared to INFU's ROE of +0.14%. Regarding short-term risk, BDX is less volatile compared to INFU. This indicates lower risk in terms of short-term price fluctuations for BDX.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BDX vs KRMD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas KRMD's P/E ratio is -95.75. In terms of profitability, BDX's ROE is +0.05%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, BDX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BDX vs PDEX Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas PDEX's P/E ratio is 19.34. In terms of profitability, BDX's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, BDX is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
BDX vs MBOT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas MBOT's P/E ratio is -6.58. In terms of profitability, BDX's ROE is +0.05%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, BDX is less volatile compared to MBOT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BDX vs AKYA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDX's ROE is +0.05%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
BDX vs STSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDX's ROE is +0.05%, compared to STSS's ROE of -1.66%. Regarding short-term risk, BDX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
BDX vs DXR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas DXR's P/E ratio is 27.33. In terms of profitability, BDX's ROE is +0.05%, compared to DXR's ROE of +0.22%. Regarding short-term risk, BDX is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for BDX.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BDX vs OMIC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDX's ROE is +0.05%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BDX vs IGAP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDX's ROE is +0.05%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, BDX is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
BDX vs NEPH Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas NEPH's P/E ratio is 50.86. In terms of profitability, BDX's ROE is +0.05%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, BDX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BDX vs MLSS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas MLSS's P/E ratio is -6.50. In terms of profitability, BDX's ROE is +0.05%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, BDX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BDX vs POCI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas POCI's P/E ratio is -6.07. In terms of profitability, BDX's ROE is +0.05%, compared to POCI's ROE of -0.37%. Regarding short-term risk, BDX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BDX vs SDC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BDX vs HBIO Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas HBIO's P/E ratio is -16.81. In terms of profitability, BDX's ROE is +0.05%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, BDX is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
BDX vs IVC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDX's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BDX vs RVP Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas RVP's P/E ratio is -2.06. In terms of profitability, BDX's ROE is +0.05%, compared to RVP's ROE of -0.08%. Regarding short-term risk, BDX is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BDX.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BDX vs ZJYL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, BDX's ROE is +0.05%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
BDX vs FEMY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas FEMY's P/E ratio is -10.25. In terms of profitability, BDX's ROE is +0.05%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, BDX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BDX vs RGNT Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas RGNT's P/E ratio is -0.08. In terms of profitability, BDX's ROE is +0.05%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BDX vs NSTG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BDX vs NXGL Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas NXGL's P/E ratio is -1.13. In terms of profitability, BDX's ROE is +0.05%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, BDX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BDX vs POAI Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas POAI's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.05%, compared to POAI's ROE of -107.05%. Regarding short-term risk, BDX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
BDX vs LUCY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas LUCY's P/E ratio is -0.39. In terms of profitability, BDX's ROE is +0.05%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, BDX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BDX vs MHUA Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDX's ROE is +0.05%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BDX vs NXGLW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, BDX's ROE is +0.05%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, BDX is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BDX.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BDX vs GMVD Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDX's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BDX vs GMVDW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BDX vs AVGR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDX's ROE is +0.05%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BDX vs LUCYW Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, BDX's ROE is +0.05%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, BDX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
BDX vs GCTK Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas GCTK's P/E ratio is -0.01. In terms of profitability, BDX's ROE is +0.05%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, BDX is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GCTK's competition here
Apria, Inc. (NASDAQ: APR)
BDX vs APR Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas APR's P/E ratio is 22.59. In terms of profitability, BDX's ROE is +0.05%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDX.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
BDX vs IIN Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDX's ROE is +0.05%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
BDX vs ALOG Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDX's ROE is +0.05%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BDX vs ATRS Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDX's ROE is +0.05%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
BDX vs IVTY Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDX's ROE is +0.05%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IVTY's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BDX vs HRC Comparison July 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 56.6B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDX is priced at $156.36 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 11.62, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDX's ROE is +0.05%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HRC's competition here